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OBJECTIVES We examined the effect of mechanical unloading with ventricular assist device (VAD) therapy
on myocardial inducible nitric oxide synthase (iNOS) expression and cardiomyocyte apoptosis
in patients with end-stage heart failure (HF).
BACKGROUND Despite advances in medical therapy, HF continues to be a progressive and ultimately fatal
disorder. High levels of iNOS expression are present in the myocardium of failing hearts,
suggesting a potential role for iNOS in HF progression.
METHODS Inducible NOS protein expression was analyzed by Western blotting and cardiomyocyte
apoptosis by terminal deoxynucleotidyltransferase dUTP nick end-labeling (TUNEL) in
myocardial samples from failing hearts. Included in these analyses were tissues from 9 patients
at the time of transplantation (HF-transplant group), 10 patients at the time of VAD
insertion (pre-VAD group), and 11 patients undergoing transplant after VAD support
(post-VAD group). Seven control samples were obtained at autopsy.
RESULTS Low or undetectable levels of iNOS were present in controls (0.005  0.002). The
HF-transplant and pre-VAD myocardial specimens exhibited a marked increase in iNOS
expression (1.48  0.34 and 1.29  0.26, respectively; p  0.01 for both vs. controls). The
increase in iNOS expression was reversed in the post-VAD group (0.36  0.16; p  0.01 vs.
HF-transplant and pre-VAD groups). The rate of TUNEL-positive cardiomyocytes was high
in the pre-VAD group and significantly lower in the post-VAD group (0.64  0.15% in
pre-VAD group and 0.16  0.07% in post-VAD group; p  0.01). The iNOS levels
correlated significantly with cardiomyocyte apoptosis (r  0.66, p  0.01).
CONCLUSIONS Therapy with VAD normalizes iNOS expression in association with diminished cardiomy-
ocyte apoptosis in the failing heart. Further work is required to define whether a causal
relationship exists between iNOS and cardiomyocyte apoptosis. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.09045:1419–24) © 2005 by the American College of Cardiology Foundation
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peart failure (HF) continues to be a major public health
roblem, with an estimated prevalence of nearly five
illion people in the U.S. (1). Despite advances in
See page 1425
edical treatment, HF often is progressive, eventually
eading to functional decline and death (2–4). The patho-
hysiologic mechanisms underlying HF progression are
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Manuscript received March 12, 2004; revised manuscript received May 17, 2004,
ccepted May 18, 2004.umerous. One hypothesis proposes that excessive nitric
xide (NO) production contributes to HF progression and
eft ventricular (LV) dysfunction (5,6).
There are three known members of the nitric oxide
ynthase (NOS) family (reviewed by Balligand and Can-
on [5]): neuronal NOS (nNOS, or NOS I), inducible
OS (iNOS, or NOS II), and endothelial or constitutive
OS (eNOS, or NOS III). Cardiac myocytes constitutively
xpress eNOS (7). Endothelial nitric oxide synthase-
ependent NO production is regulated by the binding of
almodulin, which is catalyzed by increased intracellular
alcium and results in relatively low levels of NO pro-
uction. In contrast, iNOS has a high affinity for cal-
odulin at low calcium concentrations, and thus, its
ctivity is independent of intracellular calcium. As a
esult, iNOS-dependent NO production is regulated
rimarily by alterations in iNOS protein abundance.
ecent studies have shown that iNOS is either undetect-
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VAD Therapy Normalizes Myocardial iNOS May 3, 2005:1419–24ble or detected at only low levels in healthy human
earts, but it is expressed at high levels in the myocar-
ium of failing hearts (8,9).
In severe, end-stage HF, ventricular assist device (VAD)
herapy is an accepted treatment modality to bridge critically
ll patients to heart transplantation. Ventricular assist device
upport reverses the hemodynamic aberrations present in
nd-stage failing hearts. In this setting, HF-related end-
rgan dysfunction often improves, and patients demonstrate
ignificant improvement in clinical and functional status
10,11). In this study, we hypothesized that the hemody-
amic improvements that accompany VAD support of
atients with severe, end-stage HF will decrease myocardial
NOS expression. Moreover, we sought to explore whether
AD therapy influences the level of cardiomyocyte apopto-
is in failing hearts and to examine the relationship between
poptosis and iNOS protein abundance.
ETHODS
atients. Myocardial tissue was obtained from the hearts of
onsecutive patients who had undergone heart transplanta-
ion because of severe HF due to LV systolic dysfunction.
yocardial samples were obtained from 9 patients without
revious VAD support (HF-transplant group), 10 patients
uring VAD placement (pre-VAD group), and 11 patients
t the time of heart transplantation after VAD support
post-VAD group). Normal myocardial control samples
ere obtained at the time of autopsy from seven subjects
ith no evidence of cardiac disease. This protocol was
pproved by the Institutional Review Board for Human
tudies at Tufts-New England Medical Center.
issue processing. During VAD placement, a portion of
V myocardium was harvested from the segment removed to
acilitate insertion of the apical cannula. Adipose and fibrous
issue was carefully trimmed, and segments were aliquotted
nto small transmural pieces that were snap-frozen in liquid
itrogen and stored at 70°C. One piece was fixed overnight
n 10% buffered formalin and stored in 70% ethanol until
rocessing. At the time of heart transplantation, a segment of
yocardium was removed, typically from the high lateral wall,
o avoid the infarct zone. The segment was trimmed, aliquot-
Abbreviations and Acronyms
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
HF  heart failure
iNOS  inducible nitric oxide synthase
LV  left ventricular
NO  nitric oxide
PBS  phosphate-buffered saline
RV  right ventricular
TNF-alpha  tumor necrosis factor-alpha
TUNEL  terminal deoxynucleotidyltransferase dUTP
nick-end labeling
VAD  ventricular assist deviceed, and stored as described earlier. testern blotting. Myocardial segments were homoge-
ized using a Bio-Spec tissue homogenizer (Bio-Spec Inc.,
artlesville, Oklahoma) at high speed in tissue lysis buffer
ontaining: 50 mmol/l NaCl, 50 mmol/l NaF, 20 mmol/l
risHCl, 10 mmol/l EDTA, 20 mmol/l Na4P2O8, 1
mol/l Na3VO4, 1% Triton, 1 mmol/l phenylmethanesul-
onyl fluoride, and protease inhibitors. Samples were centri-
uged, and the protein concentration of the supernatants
easured (BioRad Inc., Hercules, California). Samples (80
g) were separated by sodium dodecyl sulfate-polyacrylamide
el electrophoresis (SDS-PAGE; 8% to 12.5% gels). Proteins
ere transferred to nylon membranes using a standard trans-
er buffer (Tris/glycine) at 100 V for 90 min. Successful
ransfer was confirmed by ponceau stain. After blocking
ith 5% nonfat milk in 0.05% Tween in phosphate-buffered
aline (PBS), membranes were incubated with 1° antibodies
o iNOS (rabbit polyclonal, BD Biosciences, Palo Alto,
alifornia) followed by the appropriate 2° antibody (horse-
adish peroxidase-conjugated; Amersham Biosciences,
iscataway, New Jersey). Membranes were then incubated
ith enhanced chemiluminescence reagent (Amersham)
nd exposed to film. Bands were quantified by computerized
ensitometry. To normalize iNOS levels, the same
embranes were re-probed for the control protein,
lyceraldehyde-3-phosphate dehydrogenase (GAPDH), us-
ng a mouse monoclonal antibody (Research Diagnostic
nc., Flanders, New Jersey) and processed as described. The
NOS levels were expressed as a ratio to GAPDH.
erminal deoxynucleotidyltransferase dUTP nick end-
abeling (TUNEL). Five-micrometer sections were cut
rom paraffin-embedded tissue. Sections were post-fixed
y immersion in EtOH/acetic acid (V:V of 1:1) for 5
in. Sections were then incubated with terminal de-
xynucleotidyltransferase (TdT) in reaction buffer con-
aining digoxigenin-labeled uridine triphosphate for 60 min
t 37°C, followed by fluorescein isothiocyanate-tagged,
nti-digoxigenin antibody (Serologicals Corp., Norcross,
eorgia). Sections were counterstained with an anti-desmin
ntibody (Sigma, St. Louis, Missouri) and 4=,6-Diamidino-
-phenylindole dihydrochloride (DAPI). To diminish
ackground immunofluorescence, sections were immersed
n 0.1% Sudan black following DAPI staining and washed
nce in 70% EtOH. Positive controls were treated with
NAseI. Negative controls were incubated in reaction
uffer not containing TdT. A total of 3,000 nuclei (10
edium power fields) per section were counted by a blinded
bserver.
mmunohistochemistry. Paraffin-embedded tissues were
e-hydrated and treated with proteinase K for 30 min at
oom temperature. Endogenous peroxidases were blocked
y incubation of sections in 1% H2O2 in PBS for 30 min.
ections were blocked with 10% goat serum in PBS and
hen incubated with a rabbit polyclonal anti-iNOS antibody
t 1:400 dilution (Transduction Laboratories) overnight at
°C and washed in PBS. Samples were then incubated in
he secondary biotinylated antibody and stained with the
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May 3, 2005:1419–24 VAD Therapy Normalizes Myocardial iNOSolorimetric reagent diaminobenzidine using the Vector-
BC kit (Vector Laboratories, Burlingame, California).
egative controls consisted of sections incubated with
abbit immunoglobulin G at the same dilution as the
rimary antibody.
tatistics. All data are presented as the mean value 
EM. All statistical analyses were performed using com-
ercially available software (SigmaStat, version 2.03, SPSS
nc., San Rafael, California). Chi-square analyses were used
o compare distribution values among the baseline clinical
haracteristics. Normalized iNOS levels from multiple groups
ere compared by one-way analysis of variance (ANOVA),
ith the Student Neuman-Keuls test for post-hoc multiple
airwise comparisons. The time course of iNOS expression in
ost-VAD samples was analyzed using a curve-fitting algo-
ithm (Sigma Plot, version 8.0); a polynomial, non-linear,
nverse second-order regression equation (y y0 a/x b/x
2)
rovided the best-fitting curve and was applied to these data.
orrelations between normalized iNOS levels and hemody-
amic indexes or quantified TUNEL data were performed
sing simple linear regression. Hemodynamic and myocar-
ial TUNEL staining data from matched pre-VAD and
ost-VAD patients were compared by the paired t test. A p
alue of 0.05 was considered significant.
ESULTS
able 1 summarizes the clinical characteristics of patients
nd control subjects. The control group was younger than
he patient group, although this difference was only statis-
ically significant when compared with the HF-transplant
roup. Among the HF patients, there were similar propor-
ions of males and females and of patients with HF due to
n ischemic etiology. Three of the patients in the post-VAD
roup were supported with a biventricular device and eight
ith a left VAD only. Symptom duration was shorter in the
ost-VAD group than in the HF-transplant group (p 0.05),
ut not compared with the pre-VAD group. Seven of the
atients from whom myocardial samples were obtained
efore VAD implantation also supplied samples at the time
f transplant after VAD support. The mean duration of
Table 1. Clinical Characteristics
Controls
(n  7)
Age (yrs) 38  7
Gender (M/F) 6/1
Etiology (% CAD)
Symptom duration (months)
NYHA functional class
I
II
III
IV
EF (%)
VAD support (days)
*p  0.05 vs. controls. †p  0.05 vs. HF-transplant group.
CAD  coronary artery disease; EF  ejection fraction; F  fe
Heart Association; VAD  ventricular assist device.AD support in the post-VAD group was 113 days (range
2 to 280). Symptoms in the post-VAD group improved
uring the period of mechanical support. The three patients
ho required biventricular assist were ambulating to a
imited extent. Among the other eight VAD patients, one
equired continued inotropic treatment for right ventricular
RV) dysfunction, and the remaining seven patients had no
vert symptoms of HF.
To compare normalized iNOS levels among all groups,
ne-way ANOVA was performed and was significant (p 
.001). As shown in Figure 1A, iNOS protein levels were
ow in the control myocardial samples (ratio of densitomet-
ic units for iNOS/GAPDH protein: 0.005  0.002).
evels of iNOS protein were markedly increased in the
F-transplant group (iNOS/GAPDH  1.48  0.34) and
re-VAD group (1.29  0.26; p  0.01 vs. control group
or both) (Fig. 1). The increase in iNOS protein expression in
ailing hearts was observed in both ischemic and nonischemic
ilated cardiomyopathies. After mechanical unloading with
AD support, myocardial iNOS protein abundance decreased
ignificantly compared with the HF-transplant and pre-VAD
roups, respectively (iNOS/GAPDH  0.36  0.16; p 
.01 vs. HF and pre-VAD groups, p  NS vs. controls)
Fig. 1). A representative iNOS Western blot of myocardial
ysates obtained from three patients from whom samples were
btained before and after VAD support (“matched” group) is
hown in Figure 1B, and individualized data from all seven
atients from whom matched samples were obtained both
efore and after VAD support are shown in Figure 1C.
his graph demonstrates that iNOS protein levels de-
reased in six of the seven patients after VAD support.
he level of iNOS protein increased in one of the seven
atients with matched samples before and after VAD
upport; in this patient, the post-VAD sample was obtained
nly 12 days after device insertion when the patient under-
ent heart transplantation. Interestingly, the patient with a
ore modest decrease in iNOS abundance (Patient #3 in
igure 1A) was on continued inotropic therapy for RV
ysfunction while awaiting heart transplantation. To deter-
ine whether the observed changes in myocardial iNOS
Transplant
n  9)
Pre-VAD
(n  10)
Post-VAD
(n  11)
6  3* 51  3 48  4
7/2 9/1 9/2
56% 60% 64%
.0  13.2 33.7  15.9 22.0  13.9†
0 0 0
0 0 7
6 0 3
3 10 1
.5  1.5 14.5  2.4 15.0  2.4
113  28.1
ta are expressed as the mean value  SEM.HF-
(
5
64
14
All da
male; HF  heart failure; M  male; NYHA  New York
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VAD Therapy Normalizes Myocardial iNOS May 3, 2005:1419–24rotein expression were occurring in cardiomyocytes, im-
unohistochemical localization was performed on three
atched samples before and after VAD. As shown in
igure 2, iNOS expression was readily detected in pre-VAD
amples, where it was localized to cardiomyocytes. In
ontrast, iNOS was barely detectable in the post-VAD
ection. This pattern was observed in all three matched
igure 1. (A) Bar graph demonstrating mean inducible nitric oxide
ynthase (iNOS) levels in myocardial samples from all patients in this
tudy, including control hearts without heart disease, patients with heart
ailure (HF) at the time of transplantation (HF-transplant), at the time of
entricular assist device (VAD) insertion (pre-VAD), and after VAD
upport (post-VAD). Levels of iNOS were quantified by Western blotting,
orrecting for the control protein, glyceraldehyde-3-phosphate dehydroge-
ase (GAPDH). *p  0.01 vs. control; †p  0.05 vs. HF-transplant and
re-VAD groups. (B) Representative iNOS Western blot from three
atients with matched pre- and post-VAD myocardial samples. All three
amples demonstrate a notable decrease in iNOS within the myocardium
fter VAD support. The corresponding Western blot for the control
rotein, GAPDH, performed on the same membrane, is shown in the
ower panel. The positive control (Con) was cell lysate from cultured
ardiomyocytes stimulated with lipopolysaccharide. (C) Line graphs rep-
esenting the change in iNOS protein levels from myocardial samples
btained from the same patient before and after VAD therapy (n  7). Six
f seven patients demonstrated a marked decrease in iNOS.pecimens. (The time course of iNOS expression after VAD support
as also analyzed. Out of all 11 patients in the post-VAD
roup, only three had a normalized iNOS level greater than
he mean of 0.36. Two of these were from patients who had
ndergone transplantation within 12 and 21 days after
AD insertion. The third had a normalized iNOS level of
.6 late after VAD insertion (280 days). Thus, with the
xception of this sample, there was a rapid, time-dependent
ecrease in iNOS protein abundance after VAD support
p  0.09 for non-linear regression) (Fig. 3).
We then focused specifically on data pertaining to the
ubjects from whom matched myocardial samples were ob-
ained both before and after VAD support. Hemodynamics
rom these patients obtained immediately before and during
AD support are shown in Table 2. There was a significant
ise in the cardiac index with VAD support, from 1.9  0.1
/min/m2 to 2.5  0.2 l/min/m2, coupled with a significant
ecrease in all right heart pressure measurements, consistent
ith marked hemodynamic improvement during VAD sup-
ort. Normalized iNOS levels correlated strongly with the
ulmonary capillary wedge pressure (r  0.78, p  0.01) and
ulmonary arterial systolic (r  0.62, p  0.05) and diastolic
ressures (r  0.73, p  0.01). A non-significant, negative
orrelation existed between normalized iNOS protein abun-
ance and the cardiac index (r  0.425, p  NS).
We next explored the effect of VAD therapy on cardio-
yocyte apoptosis, as assessed by TUNEL staining per-
ormed on matched pre- and post-VAD myocardial samples
rom these same seven subjects. The percent TUNEL-
ositive cardiomyocytes in the pre-VAD apical samples was
.64 0.15%, the rate of which was similar to that observed
n the lateral wall segments obtained in the HF-transplant
roup not supported with a VAD (0.74  0.61%). The
ercent TUNEL-positive cardiomyocytes in the matched
ost-VAD samples decreased to 0.16  0.07% (p  0.01).
he rate of TUNEL-positive cardiomyocytes within these
amples correlated significantly with normalized iNOS lev-
ls (r  0.66, p  0.01) (Fig. 4).
ISCUSSION
n this study, we have confirmed the findings of other
nvestigators (8,9), demonstrating markedly increased ex-
ression of iNOS within the myocardium of failing human
earts. We now extend these earlier observations further by
emonstrating that ventricular unloading with a mechanical
ssist device markedly decreases iNOS abundance within
ardiomyocytes of the failing heart. Furthermore, we ob-
erved a significant reduction in cardiomyocyte apoptosis
uring VAD therapy. Our findings therefore demonstrate
hat mechanical unloading of the heart normalizes myocar-
ial iNOS expression in direct association with a reduction
n cardiomyocyte apoptosis.
Several recent studies have demonstrated increased pro-
rammed cell death within cardiomyocytes of failing hearts
12,13), and both clinical and experimental evidence suggests
t
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May 3, 2005:1419–24 VAD Therapy Normalizes Myocardial iNOShat cardiomyocyte apoptosis contributes to HF progression
14,15). The role of iNOS in the pathophysiology of HF
rogression and in cardiomyocyte apoptosis remains unclear.
xperimental studies have shown that high levels of NO
nhibit the cardiomyocyte-shortening velocity, in part by acti-
ating guanylate cyclase and increasing cyclic guanosine mono-
hosphate (16,17). High concentrations of NO have also been
hown to induce cardiomyocyte apoptosis (18). In this manner,
levations in iNOS expression within cardiomyocytes of the
ailing heart may contribute to the pathogenesis of progressive
V remodeling and HF. In transgenic mice, cardiac-specific
verexpression of iNOS leads to cardiac fibrosis, dilation, and
remature death (19), although another group of investigators
eported no demonstrable phenotype accompanying iNOS
verexpression in the mouse heart (20). Sam et al. (21) recently
emonstrated that six months after a myocardial infarction, the
xtent of LV dysfunction and myocardial apoptosis were
iminished in iNOS knockout mice, supporting a detrimental
igure 2. Representative inducible nitric oxide synthase (iNOS) immunoh
lin G in place of primary antibody). (Middle) Pre-VAD sample dem
ytoplasm. (Right) Post-VAD myocardial sample obtained from the same p
n this sample. VAD  ventricular assist device.
igure 3. Line graph demonstrating the level of normalized inducible
itric oxide synthase (iNOS) protein abundance versus duration of ven-
ricular assist device (VAD) support. A time-dependent decrease in iNOSp

bundance is apparent during VAD support. p  0.09 for non-linear
egression.ole of iNOS in this chronic HF model. Hence, the normal-
zation of iNOS expression after VAD support observed here
ay contribute to improved cardiomyocyte survival and signif-
cant functional recovery of the myocardium noted in some
atients after mechanical support (10,22–26). Indeed, our own
ata presented here show that iNOS abundance correlates
irectly to the percent TUNEL-positive cardiomyocytes, sup-
orting a potential causal association between iNOS and
ardiomyocyte apoptosis.
The mechanism by which VAD therapy normalizes myo-
ardial iNOS expression cannot be deduced from our findings.
owever, within cardiomyocytes in vitro, tumor necrosis
actor-alpha (TNF-alpha) and interleukin-6, both of which are
levated in the failing heart, induce iNOS transcription
hrough the activation of nuclear factor kappa-B (NF-
appa-B) (27). A recent study by Torre-Amione et al. (28)
emonstrated that the expression of TNF-alpha decreases after
AD support. Correspondingly, the level of NF-kappa-B
ctivation was also recently shown to decrease within the
yocardium of failing hearts after VAD support (22). Thus,
lterations in iNOS expression may be a critical downstream
vent in these signaling and transcription factor alterations.
tudy limitations. In this study, we did not measure iNOS
nzymatic activity. Nonetheless, previous reports have demon-
able 2. Hemodynamics Before and After Ventricular Assist
evice Support
Pre-VAD Group
(n  7)
Post-VAD Group
(n  7)
A (mm Hg) 16  2 10  2*
AS (mm Hg) 59  9 31  6*
AD (mm Hg) 30  3 13  2†
CWP (mm Hg) 28  3 14  3†
I (l/min/m2) 1.9  0.1 2.5  0.2*
p  0.05 vs. pre-VAD. †p  0.01 vs. pre-VAD. These data pertain only to those
atients from whom matched samples were obtained before and after VAD support.
ll data are presented as the mean value  SEM.
CI  cardiac index; PAD  pulmonary artery diastolic pressure; PAS 
emical stains. (Left) Negative control (non-immune, rabbit immunoglob-
ting positively stained cardiomyocytes with iNOS localized within the
t shown in Figure 1B. Inducible NOS immunostaining is barely detectableistoch
onstra
atienulmonary artery systolic pressure; PCWP pulmonary capillary wedge pressure; RA
right atrial; VAD  ventricular assist device.
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VAD Therapy Normalizes Myocardial iNOS May 3, 2005:1419–24trated that an increase in iNOS enzymatic activity coincides
ith increased protein expression in failing hearts (29). We
lso did not control for preoperative and postoperative medical
egimens that may have altered iNOS expression in failing
earts. However, it is unlikely that drug regimens after VAD
ould have differentially influenced iNOS levels, as these
egimens are standardized and nearly identical for all patients,
ith the exception of the one patient who remained on
notropic therapy for RV failure after LVAD placement.
onclusions. This study demonstrates that iNOS protein
xpression is markedly increased in the hearts of patients with
evere HF before heart transplantation. We extend previous
bservations by now showing that mechanical unloading with
AD therapy decreases iNOS protein abundance in associa-
ion with a decrease in the rate of cardiomyocyte apoptosis.
oreover, we further show that there is a significant correla-
ion between iNOS protein abundance and cardiomyocyte
poptosis. The extent to which a VAD-induced decrease in
NOS protein abundance contributes to a decrease in cardio-
yocyte cell death and/or reversal of LV dysfunction seen in
ome patients with VAD support will require further
nvestigation.
eprint requests and correspondence: Dr. Richard D. Patten,
olecular Cardiology Research Institute, New England Medical
enter, Box #80, 750 Washington Street, Boston, Massachusetts
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